Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 1

Status

Completed 6

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 9Breast 8Tumor-Agnostic 6Thoracic 3Other hematologic neoplasm 3Lymphoid 3Gynecologic 3Sarcoma 2Genitourinary 2Gastrointestinal 2Dermatologic 2Myeloid 1Head & Neck 1CNS 1

Conditions

Neoplasms 4Neoplasm Metastasis 2

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × ixabepilone × Tumor-Agnostic × Clear all
NCT00207090 2020-11-02

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

R-Pharm

Phase 1 Completed
19 enrolled 28 charts
Tumor-Agnostic

Neoplasms

NCT00717704 2020-08-05

Solid Tumors Using Ixabepilone and Dasatinib

Medstar Health Research Institute

Phase 1 Completed
19 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00207129 2017-01-30

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

R-Pharm

Phase 1 Completed
25 enrolled
Tumor-Agnostic

Neoplasms

NCT00362830 2016-09-19

A Study of the Alternative Administration of Ixabepilone and Vinflunine

Bristol-Myers Squibb

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

NCT00422097 2016-03-10

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

R-Pharm

Phase 1 Completed
40 enrolled 25 charts
Tumor-Agnostic

Neoplasms

NCT00798252 2015-07-07

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Bristol-Myers Squibb

Phase 1 Completed
111 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡